blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3018202

EP3018202 - E2EPF Ubiquitin carrier protein-von-Hippel-Lindau interaction and uses of thereof [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.05.2019
Database last updated on 15.06.2024
FormerThe patent has been granted
Status updated on  25.05.2018
FormerGrant of patent is intended
Status updated on  12.03.2018
FormerExamination is in progress
Status updated on  21.07.2017
FormerRequest for examination was made
Status updated on  18.11.2016
Most recent event   Tooltip03.07.2020Lapse of the patent in a contracting state
New state(s): CY, HU		published on 05.08.2020  [2020/32]
Applicant(s)For all designated states
Korea Research Institute of Bioscience and Biotechnology
125 Gwahak-ro, Yuseong-gu
Daejeon 34141 / KR
[2018/30]
Former [2018/26]For all designated states
Korea Research Institute of Bioscience and Biotechnology
125 Gwahak-ro
Yuseong-gu
Daejeon 305-806 / KR
Former [2016/19]For all designated states
Korea Research Institute of Bioscience and Biotechnology
111 Gwahangno
Yuseong-gu
Daejeon 305-806 / KR
Inventor(s)01 / Im, Dong-Soo
No:107-604 Hanwool Apt.
Sinsung-dong
Yuseong-gu
Daejeon 305-345 / KR
02 / Jung, Cho-Rok
504 City Villa
Bongmyong-dong
640-70 Yuseong-gu
Daejeon 305-301 / KR
03 / Hwang, Kyung-Sun
106-6 Jayang-dong
Dong-gu
Daejeon 308-830 / KR
04 / Jung Hwa, Lim
125 Gwahak-ro
Yuseong-gu
Daejeon 305-806 / KR
 [2016/19]
Representative(s)Office Freylinger
P.O. Box 48
8001 Strassen / LU
[2016/19]
Application number, filing date15158221.013.11.2006
[2016/19]
Priority number, dateKR2005010801411.11.2005         Original published format: KR 20050108014
[2016/19]
Previously filed application, dateWO2006KR0474913.11.2006
[2016/19]
Filing languageKO
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3018202
Date:11.05.2016
Language:EN
[2016/19]
Type: B1 Patent specification 
No.:EP3018202
Date:27.06.2018
Language:EN
[2018/26]
Search report(s)(Supplementary) European search report - dispatched on:EP13.04.2016
ClassificationIPC:C12N9/00, A61K38/53, // A61P9/10
[2016/19]
CPC:
C12N9/93 (EP,US); C07K1/00 (KR); A61P35/00 (EP);
A61P43/00 (EP); A61P9/10 (EP); C07K1/06 (KR);
C07K14/4703 (EP,US); C07K14/4738 (EP,US); C12N15/1137 (EP,US);
C12N15/86 (KR); C12N15/867 (KR); C12Y603/02019 (EP,US);
C12N2310/111 (EP,US); C12N2310/14 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/51]
Former [2016/19]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:E2EPF-Ubiquitinträger-Protein-von-Hippel-Lindau-Interaktion und Verwendungen davon[2016/19]
English:E2EPF Ubiquitin carrier protein-von-Hippel-Lindau interaction and uses of thereof[2016/19]
French:Interaction avec la protéine porteuse d'ubiquitine E2EPF-von Hippel Lindau et ses utilisations[2018/14]
Former [2016/19]Interaction de maladie de protéine von Hippel Lindau et support d'ubiquitine E2EPF et utilisations associées
Examination procedure09.03.2015Date on which the examining division has become responsible
11.11.2016Amendment by applicant (claims and/or description)
11.11.2016Examination requested  [2016/51]
19.07.2017Despatch of a communication from the examining division (Time limit: M04)
17.11.2017Reply to a communication from the examining division
13.03.2018Communication of intention to grant the patent
25.04.2018Fee for grant paid
25.04.2018Fee for publishing/printing paid
25.04.2018Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP06812582.2  / EP1954709
Opposition(s)28.03.2019No opposition filed within time limit [2019/23]
Fees paidRenewal fee
09.03.2015Renewal fee patent year 03
09.03.2015Renewal fee patent year 04
09.03.2015Renewal fee patent year 05
09.03.2015Renewal fee patent year 06
09.03.2015Renewal fee patent year 07
09.03.2015Renewal fee patent year 08
09.03.2015Renewal fee patent year 09
30.11.2015Renewal fee patent year 10
19.10.2016Renewal fee patent year 11
13.11.2017Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU13.11.2006
AT27.06.2018
CY27.06.2018
CZ27.06.2018
DK27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
MC27.06.2018
NL27.06.2018
PL27.06.2018
PT27.06.2018
RO27.06.2018
SE27.06.2018
SI27.06.2018
SK27.06.2018
TR27.06.2018
BG27.09.2018
GR28.09.2018
IS27.10.2018
IE13.11.2018
LU13.11.2018
BE30.11.2018
CH30.11.2018
FR30.11.2018
LI30.11.2018
[2020/32]
Former [2020/28]AT27.06.2018
CZ27.06.2018
DK27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
MC27.06.2018
NL27.06.2018
PL27.06.2018
PT27.06.2018
RO27.06.2018
SE27.06.2018
SI27.06.2018
SK27.06.2018
TR27.06.2018
BG27.09.2018
GR28.09.2018
IS27.10.2018
IE13.11.2018
LU13.11.2018
BE30.11.2018
CH30.11.2018
FR30.11.2018
LI30.11.2018
Former [2020/16]AT27.06.2018
CZ27.06.2018
DK27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
MC27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SI27.06.2018
SK27.06.2018
TR27.06.2018
BG27.09.2018
GR28.09.2018
IS27.10.2018
IE13.11.2018
LU13.11.2018
BE30.11.2018
CH30.11.2018
FR30.11.2018
LI30.11.2018
Former [2019/51]AT27.06.2018
CZ27.06.2018
DK27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
MC27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SI27.06.2018
SK27.06.2018
BG27.09.2018
GR28.09.2018
IS27.10.2018
IE13.11.2018
LU13.11.2018
BE30.11.2018
CH30.11.2018
FR30.11.2018
LI30.11.2018
Former [2019/49]AT27.06.2018
CZ27.06.2018
DK27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
MC27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SI27.06.2018
SK27.06.2018
BG27.09.2018
GR28.09.2018
IS27.10.2018
IE13.11.2018
LU13.11.2018
CH30.11.2018
FR30.11.2018
LI30.11.2018
Former [2019/48]AT27.06.2018
CZ27.06.2018
DK27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
MC27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SI27.06.2018
SK27.06.2018
BG27.09.2018
GR28.09.2018
IS27.10.2018
IE13.11.2018
LU13.11.2018
CH30.11.2018
LI30.11.2018
Former [2019/40]AT27.06.2018
CZ27.06.2018
DK27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
MC27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SI27.06.2018
SK27.06.2018
BG27.09.2018
GR28.09.2018
IS27.10.2018
LU13.11.2018
CH30.11.2018
LI30.11.2018
Former [2019/37]AT27.06.2018
CZ27.06.2018
DK27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
MC27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SI27.06.2018
SK27.06.2018
BG27.09.2018
GR28.09.2018
IS27.10.2018
LU13.11.2018
Former [2019/34]AT27.06.2018
CZ27.06.2018
DK27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
MC27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SK27.06.2018
BG27.09.2018
GR28.09.2018
IS27.10.2018
LU13.11.2018
Former [2019/33]AT27.06.2018
CZ27.06.2018
DK27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
MC27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SK27.06.2018
BG27.09.2018
GR28.09.2018
IS27.10.2018
Former [2019/26]AT27.06.2018
CZ27.06.2018
DK27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SK27.06.2018
BG27.09.2018
GR28.09.2018
IS27.10.2018
Former [2019/12]AT27.06.2018
CZ27.06.2018
EE27.06.2018
ES27.06.2018
FI27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SK27.06.2018
BG27.09.2018
GR28.09.2018
IS27.10.2018
Former [2019/11]AT27.06.2018
CZ27.06.2018
EE27.06.2018
FI27.06.2018
IT27.06.2018
LT27.06.2018
LV27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SK27.06.2018
BG27.09.2018
GR28.09.2018
IS27.10.2018
Former [2019/10]AT27.06.2018
CZ27.06.2018
EE27.06.2018
FI27.06.2018
LT27.06.2018
LV27.06.2018
NL27.06.2018
PL27.06.2018
RO27.06.2018
SE27.06.2018
SK27.06.2018
BG27.09.2018
GR28.09.2018
IS27.10.2018
Former [2019/09]EE27.06.2018
FI27.06.2018
LT27.06.2018
LV27.06.2018
NL27.06.2018
SE27.06.2018
BG27.09.2018
GR28.09.2018
IS27.10.2018
Former [2019/08]FI27.06.2018
LT27.06.2018
LV27.06.2018
NL27.06.2018
SE27.06.2018
BG27.09.2018
GR28.09.2018
IS27.10.2018
Former [2019/03]FI27.06.2018
LT27.06.2018
LV27.06.2018
NL27.06.2018
SE27.06.2018
BG27.09.2018
GR28.09.2018
Former [2018/52]FI27.06.2018
LT27.06.2018
LV27.06.2018
SE27.06.2018
BG27.09.2018
GR28.09.2018
Former [2018/51]FI27.06.2018
LT27.06.2018
LV27.06.2018
SE27.06.2018
BG27.09.2018
Former [2018/49]FI27.06.2018
LT27.06.2018
SE27.06.2018
BG27.09.2018
Former [2018/47]FI27.06.2018
LT27.06.2018
Documents cited:Search[A]WO2004064711  (VERENIGING HET NL KANKER I [NL], et al) [A] 1-10 * the whole document *;
 [XP]WO2006044366  (NOVARTIS AG [CH], et al) [XP] 1-5 * page 26, paragraph 10. - page 32, paragraph 15. *;
 [XD]  - LIU ZHI ET AL, "Characterization of a novel keratinocyte ubiquitin carrier protein", JOURNAL OF BIOLOGICAL CHEMISTRY, (1996), vol. 271, no. 5, doi:10.1074/JBC.271.5.2817, ISSN 0021-9258, pages 2817 - 2822, XP002387892 [XD] 1-5 * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.271.5.2817
 [AD]  - WAGNER K W ET AL, "Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin", ONCOGENE, (20040826), vol. 23, no. 39, ISSN 0950-9232, pages 6621 - 6629, XP002387890 [AD] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.1038/sj.onc.1207861
 [A]  - OHH M ET AL, "Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein", NATURE CELL BIOLOGY, (20000701), vol. 2, no. 7, ISSN 1465-7392, pages 423 - 427, XP002388870 [A] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.1038/35017054
 [A]  - MAYNARD AND M OHH M A, "Molecular Targets from VHL studies into the oxygen-sensing pathway", CURRENT CANCER DRUG TARGETS, (200508), vol. 5, no. 5, doi:10.2174/1568009054629672, ISSN 1568-0096, pages 345 - 356, XP008126417 [A] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.2174/1568009054629672
 [XP]  - JUNG CHO-ROK ET AL, "E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis", NATURE MEDICINE, (200607), vol. 12, no. 7, ISSN 1078-8956, pages 809 - 816, XP002603020 [XP] 1-5 * the whole document *

DOI:   http://dx.doi.org/10.1038/NM1440
by applicantEP0031080
 EP0412765
 WO9818480
 WO9845331
 KR20010006460
 WO03006477
 KR20030013795
 KR100375890B
 WO03029292
 WO2004015107
 US6703204
 KR20050012082
 KR20050018140
    - LIU Z. ET AL., JBC, (1992), vol. 267, pages 15829 - 15835
    - LIU Z. ET AL., JBC, (1996), vol. 271, pages 2817 - 2822
    - BABOSHINA OV; HAAS AL., JBC, (1996), vol. 271, pages 2823 - 2831
    - MUTTER GL; BAAK JPA., J CLIN PATHOL., (2005), vol. 58, no. L, pages 1 - 6
    - WELSH JB ET AL., PNAS USA, (2001), vol. 98, pages 1176 - 1181
    - WAGNER KW, ONCOGENE, (2004), vol. 23, pages 6621 - 6629
    - KAELIN WG JR., NAT REV CANCER, (2002), vol. 2, pages 673 - 682
    - CURR OPI GEN DEV, (2003), vol. 13, pages 56 - 60
    - TRENDS MOL MED, (2004), vol. 10, pages 146 - 149
    - TRENDS MOL MED, (2004), vol. 10, pages 466 - 472
    - GENE THER, (2003), vol. 10, pages 2081 - 2089
    - NAT REV CANCER, (2002), vol. 2, pages 673 - 682
    - NAT MED, (2003), vol. 9, pages 677 - 684
    - NAT, (1992), vol. 359, pages 843 - 845
    - NAT, (1992), vol. 359, pages 845 - 848
    - PNAS USA, (1997), vol. 94, pages 8104 - 8109
    - CAN RES, (2000), vol. 60, pages 4010 - 4015
    - OPHTHALMOLOGY, (2002), vol. 109, pages 1745 - 1751
    - PROC AM SOC CLIN ONCOL, (2002), vol. 21, page 15
    - YLA-HERTTUALA S; ALITALO K, NAT MED., (2003), vol. 9, no. 6, pages 694 - 701
    - KHAN TA ET AL., GENE THER, (2003), vol. 10, no. 4, pages 285 - 291
    - LEUNG DW ET AL., SCIENCE, (19881208), vol. 246, no. 4935, pages 1306 - 1309
    - DVORAK HF ET AL., AM J PATHOL., (1995), vol. 146, no. 5, pages 1029 - 1039
    - MKINEN K ET AL., MOL. THER., (2002), vol. 6, pages 127 - 133
    - DOR Y ET AL., EMBO J., (2002), vol. 21, pages 1939 - 1947
    - MAEKIMEN K ET AL., MOL THER, (2002), vol. 6, pages 127 - 133
    - STEWART DJ ET AL., CIRCULATION, (2002), vol. 106, pages 23 - 26
    - RAJAGOPALAN S ET AL., J AM COLL CARDIL, (2003), vol. 41, page 1604
    - VINCENT KA ET AL., CIRCULATION, (2000), vol. 102, pages 2255 - 2261
    - ELBASHIR ET AL., NATURE, (20010524), vol. 411, no. 6836, pages 494 - 498
    - TETRAHEDRON LETT., (1991), vol. 32, pages 30005 - 30008
    - NAGAI ET AL., TETRAHEDRON LETT, (1985), vol. 26, page 647
    - EWENSON ET AL., J MED CHEM, (1986), vol. 29, page 295
    - GORDON ET AL., BIOCHEM BIOPHYS RES COMMUN, (1985), vol. 126, page 419
    - Remington's Pharmaceutical Science, MACK PUBLISHING COMPANY
    - MOL THER., (2004), vol. 10, pages 938 - 949
    - EMBO J, (2003), vol. 22, pages 5241 - 5250
    - PNAS USA, (2000), vol. 97, pages 8507 - 8512
    - GENES & DEVELOPMENT, (1998), vol. 12, pages 3872 - 3881
    - JBC, (2000), vol. 275, pages 14005 - 14008
    - JBC, (2000), vol. 275, pages 8945 - 8951
    - JBC, (2004), vol. 279, pages 42169 - 42181
    - JBC, (2002), vol. 277, pages 30338 - 30393
    - CURR BIOL, (1999), vol. 9, pages 1180 - 1182
    - CHEN Z ET AL., NATURE, (2005), vol. 436, pages 725 - 730
    - NAT, (1999), vol. 399, pages 271 - 299
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.